top of page

Has 2024 ushered in new trends, challenges, and opportunities for outsourcing drug and therapy development, and working with external partners? Our panel of development experts thinks so. From new platforms, modalities and technologies, to the fundamentals of process development and service-provider management, it’s a good time to take the pulse of this middle component of creating new options for patients. Outsourced Pharma Live's Louis Garguilo welcomed Nils Olsson, VP, CMC and Bioanalytical at Cerus, Perry Calias, Ph.D., Co-founder of Educational Trainers and Consultants, and Andrei Blasko, President and Chief Executive Officer of Clearview Pharma Solutions LLC for this digital event. Source: Outsourced Pharma

Two Tips for Your Outsourcing Consideration (
What Could Possibly Go Wrong? (
Backup Plans: At the Same Contract Developer or Elsewhere? (
Scope-Of-Work Strategies When Contracting with CDMOs (
FTEs, Fees-For-Service, Or Time-And-Materials? (
Don’t Fear CDMO Or Facility Change (

Outsourcing, says Andrei Blasko, President and CEO, Clearview Pharma Solutions, is all about incentives … and moving to the next CDMO when necessary.

Andrei Blasko has worked at Big Pharma and smaller companies. When outsourcing development, he advises always asking – and answering – a key question.

Our panelists get into an important discussion of what backup plans should entail to derisk outsourcing, and being one’s own “project manager” plays a role in all cases.

Nils Olsson, Cerus, and Andrei Blasko, Clearview Pharma Solutions, discuss how to scope out your scope of work for outsourcing development activities.

All three of our expert panelists have opinions and suggestions for Outsourced Pharma readers when it comes to how to hire the skilled workforce at a CDMO.

One of our most experienced outsourcing professionals pleads with Outsourced Pharma readers to make the changes necessary to bring about optimal outsourcing.

A guest column article on Preformulation of Excipients in Biologics Development was published in Bioprocess Online


Bioprocess Online, Guest Column, September 28, 2023

Plano, Texas  Preformulation of Excipients in Biologics Development by Andrei Blasko, Clearview Pharma Solutions LLC was published in 

Bioprocess Online (link) and cross-published it on two other portals, Outsourced Pharma (link) and Biosimilar Development (link).

Also, ISPE scooped up the article for its SmartBrief newsletter on September 29, 2023. 

Excipient characterization key to biologic stability

Most ingredients in drug products are excipients, and impurities in excipients are common roots of drug product instability. Novel excipients are considered active pharmaceutical ingredients for toxicity testing, impurity profiling and physicochemical characterization, but different regulatory bodies have different definitions of "novel excipient," and new regulatory guidance on genotoxic and elemental impurities as well as excipient performance and degradation testing should not be ignored, writes Andrei Blasko, president and CEO of consulting firm Clearview Pharma Solutions.

Clearview Pharma Solutions, LLC announces its relocation to Texas

Texas Secretary of State, March 2023

Plano, Texas  California Certificate of Conversion was filed with the California Secretary of State effective as of February 28, 2023

Certificate of Conversion, Plan of Conversion, and Certificate of Formation was filed with the Texas Secretary of State effective as of March 15, 2023.

Clouds Theme Room

Clearview Pharma Solutions, LLC announces two types of consulting services for drug development

San Bruno, California — Clearview Pharma Solutions LLC (, a pharma/biotech consulting company for drug development announces that is offering two types of retainer services: “Pay for Work” and “Access” Retainer.

The pharmaceutical industry is a fast-paced environment. When a challenge arises that demands a deeper level of expertise than what you currently have on staff, you want to have access to an expert right away. This allows you to keep your overhead low while being able to handle uniquely complex situations as you meet them head-on.

We offer consulting on full cycle of drug development:

  • Preformulation

  • Formulation

  • Analytical development and validation

  • Strategic long-term plan for formulation development

  • Regulatory filing

  • Due diligence and Innovation


What differentiates us from the competitor is the strong physical organic/bio-organic expertise of Founder, Dr. Andrei Blasko (evidenced by 90+ publications and patents). A high level of expertise is key to a successful drug development process. Many instabilities and/or delivery problems can be attributed to the physicochemical properties of the active ingredient and excipients and most of the time, to the impurities in excipients.

The choice of consulting retainer depends whether the client has an ongoing project with defined deliverables (“Pay for Work” Retainer) or needs to solve unforeseen problems on an ongoing basis (“Access” Retainer). Learn more about the two types of consulting retainers that Clearview Pharma Solutions LLC offers at

“By having somebody like myself on retainer, you have the peace of mind that any time something comes up you can count on me. My responses will be timely to keep your project on track. You can rest assured knowing that I am your adviser, that I am on your side, and that I will consistently support your business and help you with any of the challenges that might come up.” - Andrei Blasko, PhD, FRSC, Founder of Clearview Pharma Solutions.

“The value I deliver is far greater than the investment you are making to pay for my retainer. The monthly fee for Access retainer could prove to deliver a 5x return with significant development time reduction. If this is something that interests you, I welcome a phone conversation at your convenience.”

Andrei Blasko, PhD, FRSC
Clearview Pharma Solutions LLC

bottom of page